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ABSTRACT: p63 is an important regulator of epithelial
development expressed in diﬀerent variants containing (TA)
or lacking (ΔN) the N-terminal transactivation domain. The
diﬀerent isoforms regulate stem-cell renewal and diﬀer-
entiation as well as cell senescence. Several studies indicate
that p63 isoforms also play a role in cancer development;
however, very little is known about the role played by p63 in
regulating the cancer stem phenotype. Here we investigate the
cellular signals regulated by TAp63 and ΔNp63 in a model of
epithelial cancer stem cells. To this end, we used colon cancer
stem cells, overexpressing either TAp63 or ΔNp63 isoforms,
to carry out a proteomic study by chemical-labeling approach
coupled to network analysis. Our results indicate that p63 is
implicated in a wide range of biological processes, including metabolism. This was further investigated by a targeted strategy at
both protein and metabolite levels. The overall data show that TAp63 overexpressing cells are more glycolytic-active than ΔNp63
cells, indicating that the two isoforms may regulate the key steps of glycolysis in an opposite manner. The mass-spectrometry
proteomics data of the study have been deposited to the ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository with data set identiﬁers PXD000769 and PXD000768.
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■ INTRODUCTION
The p53/p63/p73 family is composed of strictly related
transcription factors sharing highly homologous sequences.
Thus it was supposed for a long time that these proteins could
also share functional roles.1,2 In recent years, distinct roles for
each member have emerged on the basis of new experimental
evidence. A huge number of studies demonstrated that p53 is a
master tumor suppressor gene, whose mutation is frequently
associated with cancer,3 while the role of p63 in tumor
suppression still needs more clariﬁcation. The study of the role
played by p63 is sometimes rendered more problematic by the
structural variability of protein products originating from p63
gene. Similarly to p73, p63 gene is transcribed in multiple
isoforms. The amino-terminal region of p63 may include an
acidic transactivation domain (TA isoforms) or lack this
domain (ΔN isoforms).4 Moreover alternative splicing may
originate diﬀerent transcripts responsible for variability at
protein carboxy-terminals, thus bringing about α, β, γ, δ, and ε
variants. From a structural point of view, p63α is closer to
p73α, sharing a common sterile alpha motive (SAM) domain,
absent in p53. TAp63 and ΔNp63 regulate to diﬀerent extent
the expression of their targets, which are involved in several
cellular functions such as apoptosis, cell cycle arrest, and
senescence.4,5
Altered levels of p63 were demonstrated in diﬀerent
epithelial tumors, such as in breast, head and neck, and lung,
by the use of targeted detection techniques, such as PCR, or by
using antibodies, which could not discriminate among TAp63
and ΔNp63, thus sometimes giving controversial results.6 In
particular, these studies showed that the TA isoforms are not
expressed or weakly expressed, whereas the ΔN isoforms are
expressed at higher levels.6,7 Conversely to p53, mutations of
p63 are extremely rare in tumors.7 The expression pattern
showed by the diﬀerent isoforms observed in cancer is
consistent with the concept that TAp63α may function as
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tumor suppressor, while ΔNp63α may act as an oncogene,
antagonizing p53, TAp63, and TAp73, by aﬀecting the
expression of those target genes, which are generally under
their control;8 this, however, is probably an oversimpliﬁed
vision of how these transcription factors work, and indeed
ΔNp63 contains an additional transactivation domain and has
been shown to up-regulate expression of a speciﬁc set of genes.8
Evaluation of p63 expression proﬁle also revealed in a few cases
the lack of the ΔNp63 protein in human tumors such as diﬀuse
large B-cell lymphoma (DLBCL), suggesting that this isoform
may also acts as a tumor suppressor.9 The epithelial
mesenchymal transition (EMT), a relevant process involved
in cancer cell metastasis as well as in embryogenesis, is also
known to be modulated by ΔNp63. As an example, it was
reported in a model of squamous cell carcinoma (SCC) that
during EMT, SNAIL, a regulator of cellular invasiveness, down-
regulates ΔNp63 expression and in parallel also down-regulates
E-cadherin.10 Recently, experiments conducted in prostate
cancer cells showed that both TAp63 and ΔNp63 isoforms
regulate expression of miR-205, which is essential for p63 to
explain its inhibitory eﬀect on EMT.11 In vitro and in vivo
experiments revealed that TAp63 is a suppressor of tumori-
genesis and metastasis.12 According to the proposed model,
TAp63 transcriptionally activates metastasis suppressor genes
or microRNAs, such as DICER1, mir-130b, and BHLHE41,
also known as SHARP1, and genes involved in integrin
recycling. The suppression of the metastasis mediated by
TAp63 is inhibited by aggregation with mutant p53 and by
transforming growth factor-β (TGFβ).8,12 p63 was also
reported to be involved in cancer chemosensitivity.5
Endogenous TAp63 expression was increased after drug
treatment in hepatoma cells, and the abrogation of TAp63
function caused enhanced chemoresistance. These observations
were in accordance with the pro-apoptotic activity of TAp63,
carried out through death receptor- and mitochondrial-mediate
apoptosis pathway.13 On the contrary, ΔNp63 does not show
pro-apoptotic activity but can compete with TAp63 for the
same responsive element, thus inhibiting the TAp63-mediated
apoptotic program.14
A large plethora of experimental research regarding p63
function focused not only on its involvement in cancer but also
on characterizing its pivotal role in epithelial development.5
Mutant mice that do not express p63 are born lacking limbs as
well as skin and its appendages15,16 and have markedly
abnormal prostate and bladder epithelia.17 More deepen
understanding about the distinct functions of the two isoforms,
achieved by the characterization of knockout mice for TA and
ΔNp63 isoforms, revealed that these anomalies result from the
lack of ΔNp63.18 ΔNp63 is expressed in basal epithelial cells
and is required for normal development of several epithelial
tissues, including the bladder, prostate glands and colorectal
epithelia.19 This isoform is necessary for stem-cell renewal15,20
as well as for terminal diﬀerentiation,18,21 whereas TAp63 is
implicated in maintaining stem cells in quiescence and
preventing premature aging22 and senescence.12,22 Because of
its implication in both cancer and stemness, p63 may also play a
relevant role in maintaining the cancer stem-cell phenotypes,
particularly in tumors of epithelial origin.6,14,23 Colorectal
tumors are hierarchically organized with a minor cancer stem
cells (CSCs) niche, showing self-renewal and multilineage
diﬀerentiation capacity, responsible for the formation of more
diﬀerentiated less malignant cells, making up the bulk of the
tumor.24,25 CSCs have also been implicated in drug resistance
and tumor recurrence, although the nature of this relationship
is only beginning to be clariﬁed.26 Onco-proteomics may
signiﬁcantly contribute to explore this ﬁeld, employing sensitive
methodological approaches and accurate procedures to
characterize proteins involved in the cellular processes
responsible for maintaining the CSC pool.27
In this work, we investigated the eﬀects of TAp63α and
ΔNp63α overexpression in colon CSCs, which express a low
level of the endogenous isoforms by complementary
proteomics approaches (Scheme 1). In the discovery phase,
we carried out a quantitative proteome analysis by stable
isotope dimethyl labeling to deﬁne the expression proﬁles of
the infected cells, generating raw data for unsupervised data-
mining of functional biological processes. Then, in a
subsequent validating phase, we employed a targeted analysis,
at both protein and metabolite levels, focusing, in particular, on
metabolic processes. This experimental design allowed us to
obtain an overview on cellular pathways modulated by p63,
thereby oﬀering the opportunity to better understand its
implication in maintaining the CSCs phenotype.
■ EXPERIMENTAL PROCEDURES
Puriﬁcation and Culture of CSCs
Human colon tissue fragments were obtained in accordance
with the ethical standards of the institutional committee on
human experimentation from a patient undergoing a colon
Scheme 1. Workﬂow Diagram Showing the Experimental Design
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resection for colon adenocarcinoma. Histological diagnosis was
based on microscopic features of carcinoma cells determining
the histological type and grade. Cancer tissues were extensively
washed in saline buﬀer containing antibiotics and incubated
overnight in DMEM/F12 (1:1) containing penicillin (500 IU/
mL), streptomycin (500 μg/mL) and amphotericin B (1.25 μg/
mL). Enzymatic digestion was performed using collagenase (1.5
mg/mL) and hyaluronidase (20 μg/mL) in DMEM containing
antibiotics/antimycotics for 1 h. Recovered cells were then
cultured in serum-free medium DMEM/F12 (1:1) supple-
mented with 6 mg/mL glucose, 1 mg/mL NaHCO3, 5 mM
HEPES, 2 mM L-glutamine, 4 μg/mL heparin, 4 mg/mL BSA,
10 ng/mL βFGF, 20 ng/mL EGF, 100 μg/mL transferrin
sodium salt, 25 μg/mL insulin, 9.6 μg/mL putrescine, 30 nM
sodium selenite, and 20 nM progesterone to a ﬁnal
concentration of 3 × 105 cells/mL at 37 °C in a humidiﬁed
atmosphere of 5% (v/v) CO2 in air. These culture conditions
select for immature tumor cells that slowly proliferate, giving
rise, within 2 to 3 months, to tumor cell aggregates, called
“spheres”.28
Plasmids
TAp63α-Tween and ΔNp63α-Tween expression vectors were
generated from TAp63α−pcDNA and ΔNp63α−pcDNA
constructs, kindly provided by Prof. G. Melino, University of
Rome “Tor Vergata”, Roma, Italy.29 Inserts were subcloned
into XbaI-XhoI unique sites of Tween lentiviral vector30 under
the control of hCMV promoter. This vector constitutively
expresses GFP under the control of hPGK promoter.
Lentiviral Trasduction and Flow Cytometry
Lentiviral supernatants were produced by transient cotransfec-
tion of a three-plasmid expression system in the packaging
293T cell line, using the calcium phosphate transfection kit
(K2780-01, Invitrogen). The calcium phosphate−DNA precip-
itate was removed after 9 h by washing once in PBS and
replacing the medium. Viral supernatant was collected 48 h
after transfection, ﬁltered through 0.45 μm pore nitrocellulose
ﬁlter. CSCs were plated in a six-well plate in the presence of
viral supernatant and 4 μg/mL of polybrene. Plates were
centrifuged for 45′ at 1800 revolutions/min and incubated at
37 °C for 75′ in a 5% CO2 incubator. Cells were then washed
twice and replated in fresh medium.31 Transduction eﬃciency
was assessed as the percentage of GFP-positive cells measured
by ﬂow cytometry (FACSCanto II Instrument, BD Bio-
sciences) 48 h postinfection. Data were analyzed with
CELLQuest software (BD Biosciences).
Peptides Labeling
Cells of three independent infection experiments for each
condition were lysed by sonication, and total proteins were
extracted in 6 M urea, 100 mM Tris/HCl pH 7.5 buﬀer.
Protein concentration was determined by the Bio-Rad Protein
Assay (Bio-Rad Laboratories, Hercules, CA). 50 μg for each of
the three protein extractions was pooled for condition,
precipitated by the addition of a mix of ethanol, methanol,
and acetone (ratio 2:1:1, v/v/v) and solubilized in 6 M urea,
100 mM TEAB pH 8.5, a buﬀer compatible with subsequent
dimethylation.32 25 μL of 6 M urea, 100 mM TEAB pH 8.5,
containing 100 μg of pooled protein extract was reduced and
alkylated by adding DTT (10 mM) (1 h at 36 °C) and
iodoacetamide (50 mM) (1 h at RT). Protein samples were
digested with 1:20 (w/w) sequence grade trypsin (Promega,
Madison, WI) at 36 °C overnight. Tryptic peptides were
subjected to chemical labeling by modifying the already
published protocol.32,33 Stable isotope dimethyl labeling was
achieved by the reaction of peptide primary amines (the N
terminus and the side chain of lysine residues) with
formaldehyde to generate a Schiﬀ base, rapidly reduced by
adding cyanoborohydride to the tryptic digestion. Light labeled
peptides were obtained by using formaldehyde-D0 and
cyanoborohydride, which produced a mass increase of 28 Da,
while the use of deuterated formaldehyde (formaldehyde-D2)
generated a mass increase of 32 Da, achieving the heavy labeled
samples. The labeled samples can then be mixed because the
diﬀerent isotopes do not aﬀect the behavior of the labeled
peptides in LC−MS/MS. An insigniﬁcant isotopic eﬀect in
chromatography runs has been veriﬁed by Hsu at colleagues33
and by other subsequent dedicated studies,34 so that the
coelution of paired labeled peptides (the pair of heavy and light
peptide) is expected to occur.
In MS, the diﬀerent stable isotopically labeled peptides can
be recognized by the known mass diﬀerence between them.
Finally, quantiﬁcation can be performed by comparing the
signal intensity of the diﬀerentially labeled peptides. In detail:
1.5 μL of formaldehyde-D0 (20% in water) was mixed in the
peptides mixture, vortexed, and incubated for 5 min at RT.
Then, 2.5 μL of freshly prepared sodium cyanoborohydride (1
M) was added and allowed to react for 1 h at RT. Deuterium
labeling was performed by similar procedure but by using
formaldehyde-D2 (20% in water). An extensive characterization
of dimethylation in quantitative analysis has been recently
performed by our group,35 demonstrating, in accordance with
other published works,32,33 that this approach is cheap, quick,
and applicable to any sample, including complex samples. The
completion of the reaction was evaluated by running singularly
the D0- and D2-labeled samples in nL−MS/MS by using a Q-
Tof Premier mass spectrometer (Waters, Manchester, U.K.)
operating in DDA mode.36 In the case of complete D0 or D2
reaction, it is expected that all peptides will be dimethylated (at
N-terminus) or tetramethylated (both at N-terminus and at the
side chain of lysine residue). By including dimethylation at the
N-terminus and side chain of lysine residue as a variable
modiﬁcation in the database search, all peptides of D0- and D2-
labeled samples were found to be modiﬁed (representative
database search results were reported in Supplementary Table
1S in the Supporting Information). On the contrary, when
these modiﬁcations were not applied, we did not obtain peptide
identiﬁcation.
Light and heavy labeled samples were mixed 1:1 prior to
peptide separation by isoelectric focusing. We analyzed TAp63-
D0 with CTRL-D2 (1:1) and ΔNp63-D0 with CTRL-D2 (1:1).
The inverted labeled samples were also mixed: TAp63-D2 with
CTRL-D0 (1:1) and ΔNp63-D2 with CTRL-D0 (1:1).
Immobilized pH Gradient Isoelectric Focusing (IPG-IEF)
Separation of Labeled Peptides
Mixed samples of light and heavy labeled peptides were
separated by IPG-IEF prior to mass spectrometry analysis.37−39
A solution of 8 M urea, 0.5% (v/v) IPG-buﬀer (pH 3−10 NL,
Amersham Biosciences, Buckinghamshire, U.K.), and bromo-
phenol blue in traces was added to the mixture of labeled
peptides until a ﬁnal volume of 350 μL. Isoelectric focusing was
performed in an IPGphor system (Amersham Biosciences)
using Immobiline Dry strips 18 cm, pH interval 3−10 nonlinear
at 20 °C. After 8 h of passive and 8 h of active rehydration at 30
V, peptides were focused ramping to 300 V over 2 h, holding at
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300 V for 1 h, ramping to 3500 V over 3 h, holding at 3500 V
for 3 h, successively ramping to 8000 V over 3h and plateau at
8000 V until 50 000 V/h.
nLC−MS/MS Analysis
Focused strips were cut into 15−17 pieces, and peptides were
extracted twice with a solution of 0.1% formic acid (FA) and
50% acetonitrile (1:1) and then with 100% acetonitrile,
collecting supernatants into autosampler vials. The extracted
mixtures were dried by Speed-Vac and dissolved in 20 μL of
0.1% FA. Five microliters of each sample was separated by a
Proxeon Easy-nLC II (Thermo Scientiﬁc, Waltham, MA)
chromatographic system equipped with an EASY-Column C18,
5 μm, 100 μm × 20 mm precolumn (Thermo Scientiﬁc) and
using an Acclaim PepMap100 C18, 5 μm, 75 μm × 25 mm
(Dionex, Thermo Scientiﬁc) nanoscale LC column. Mobile
phase A was water with 0.1% FA, and mobile phase B was 0.1%
FA in acetonitrile. Peptides were separated with a reverse-phase
gradient of 5−35% mobile phase B over 57 min at a ﬂow rate of
300 nL/min and a rinse with 100% mobile phase B for 10 min.
The chromatographic system was coupled online to a
MicrOTOF Q-II mass spectrometer (Bruker-Daltonics, Bre-
men, Germany) equipped with an ESI nanosprayer ion source.
During acquisition, source settings were: end plate oﬀset: −500
V; capillary = 4500 V; nebulizer = 0.4 bar; dry gas = 4 L/min;
dry temperature = 160 °C.
Spectra acquisition in the mass range 400−1400 m/z was
performed by using an Auto (MS/MS) mode method
optimized for quantitative proteomics (Bruker-Daltonics,
Bremen, Germany), setting MS spectra rate to 1.0 Hz and
the number of precursor ions to 5, using active exclusion after
two spectra, using Argon in collision gas cell, and selecting the
SILE option. By this option, it is possible to deﬁne the delta
mass introduced by the labeling approach. A delta mass of 4 Da
indicates the N-terminal dimethylation, while a delta mass of 8
Da indicates the dimethylation of both N-terminal and lysine
residue of the peptide sequence, and thus in the SILE option
we speciﬁed delta mass = 4.0251; maximum number of labels =
2; and charge range = 1−3.
Peptide Identiﬁcation and Quantiﬁcation
Spectra were processed by using Mascot Distiller v2.4.3.3 using
the default processing methods optimized for Q-TOF instru-
ment. Peptide identiﬁcation was achieved by the in-house
version of Mascot algorithm (version 2.4), interrogating Swiss-
Prot database (released version 2013_02) restricted to Homo
sapiens taxonomy (20 248 sequences). Search parameters were:
carbamidomethylation of cysteines as ﬁxed modiﬁcation,
oxidation of methionines as variable modiﬁcation, dimethyla-
tion as quantitation method, one missing cleavage allowed on
tryptic peptides, 20 ppm for peptide tolerance, 0.1 Da for
fragment tolerance, p value < 0.05 for peptide signiﬁcant value
of identiﬁcation, and decoy option active. Proteins identiﬁed
with one unique peptide were manually validated. After protein
identiﬁcation, only peptides matching the following criteria
were included in the ﬁnal quantitation analysis: p value < 0.05
for peptide signiﬁcant value, bold red, unique sequences,
standard error <0.2, correlation threshold >0.9, and fraction
threshold of at least 0.5. Because the ﬁt between the
experimental and the calculated peaks is never perfect, Distiller
allows us to accept a peptide ratio by applying the threshold of
three measures of the quality of the ﬁt: standard error, fraction,
and correlation. The standard error is the estimated error for
the calculated ratio. The correlation coeﬃcient, which considers
the shape of the peak distribution, is the estimation of the good
ﬁt between the predicted and observed precursor isotope
distributions. Fraction is the fraction of the precursor region
accounted for by the expected precursor peaks. The resulting
quantiﬁed proteins were reported in the quantitation report,
where the protein ratio type selected was “median” and the
interval of conﬁdence was expressed as geometric standard
deviation, SD(geo), which is a factor, not a diﬀerence. Finally,
only proteins with a ratio >1.3 or <0.7 and Mascot score above
40 and acceptable SD(geo) were considered in the further
analysis. Proteins were identiﬁed with FDR < 1%. The mass
spectrometry proteomics data have been deposited to the
P r o t e om eX c h a n g e C on s o r t i um ( h t t p : / /www .
proteomexchange.org) via the PRIDE partner repository40,41
with the data set identiﬁer PXD000768 and DOI: 10.6019/
PXD000768 for TAp63 and PXD000769 and DOI: 10.6019/
PXD000769 for ΔNp63. These data sets are formally associated
with the B/D-HPP initiative on Cancer and Mitochondria.
Bioinformatics Analysis
Modulated proteins identiﬁed by proteomic analysis were
further analyzed by the PANTHER Classiﬁcation System
(http://www.pantherdb.org), by The Database for Annotation,
Visualization and Integrated Discovery (DAVID) (http://
david.abcc.ncifcrf.gov/), and by Ingenuity Pathway Analysis
software v.8.8 (IPA). Using PANTHER resource, it is possible
to categorize genes by their molecular functions or biological
processes on the basis of published papers and by evolutionary
relationships to predict function when experimental evidence is
missing. DAVID provides a comprehensive set of functional
annotation tools for investigators to understand biological
meaning behind a large list of genes/proteins. IPA highlights
protein networks or pathways starting from a continuous
updated database of known protein−protein interactions based
on direct (physical) and indirect (functional) associations. The
algorithm gives back a probability score for each possible
network. Scores of 10 or higher (negative log of the p value)
have a high conﬁdence of not being generated by random
chance alone.42−44
Targeted Label-Free Quantitative Analysis
Protein extracts samples were prepared as previously described.
Tryptic peptide mixtures of the three diﬀerent conditions,
obtained by in-solution digestion as already described, were
separately analyzed by nanoACQUITY UPLC System (Waters,
Milford, MA) coupled to a Q-Tof Premier mass spectrometer
(Waters, Manchester, U.K.) operating in high-low mode.42−44
The triplicate of each condition was run. Prior to loading, a
digestion of Enolase (ENO1) from Saccharomyces cerevisiae
(Waters) was added to the sample as an internal standard to
have a ﬁnal concentration of 100 fmol/μL on column. A total of
0.6 μg of protein digestion was injected onto symmetry C18 5
μm, 180 μm × 20 mm as precolumn (Waters) for
preconcentration and desalting and separated using a NanoEase
BEH C18 1.7 μm, 75 μm × 25 cm nanoscale LC column
(Waters) maintained at 35 °C. Mobile phase A was water with
0.1% formic acid, while mobile phase B was 0.1% formic acid in
acetonitrile. Peptide separation was obtained by a gradient of
3−40% B over 150 min at ﬂow rate of 250 nL/min, followed by
a gradient of 40−90% B over 5 min and a 15 min rinse with
90% B. The Q-Tof Premier mass spectrometer was operated in
“Expression Mode” switching between low (4 eV) and high
(15−40 eV) collision energies with a scan time of 0.8 s over
50−1990 m/z mass range. Continuum LC−MS data were
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processed and searched using ProteinLynx GlobalServer v2.4
(PLGS) (Waters). Protein identiﬁcations were obtained with
the embedded ion accounting algorithm of the software and by
searching a UniProtKB/SwissProt human database. Parameters
for the database search were: automatic tolerance for precursor
ions, automatic tolerance for product ions, minimum of three
fragment ions matched per peptide, minimum of seven
fragment ions matched per protein, minimum of two peptides
matched per protein, one missed cleavage, carbamidomethyla-
tion of cysteine and oxidation of methionine as modiﬁcations,
and the false positive rate (FPR) of the identiﬁcation algorithm
<1%.
Acquired raw data were used as input ﬁles by Skyline open-
source software to perform quantitative analysis.46,47 A peptide
MS/MS spectral library of samples was created from a csv ﬁle
generated by PLGS software including peptide and fragment
ions information. Duplicate or repeated peptides and peptides
without a matching protein in the background proteome, the
UniProtKB/Swiss-Prot database restricted to Homo sapiens
taxonomy, were automatically removed. Raw data from single
sample runs were processed to generate the eXtracted Ion
Chromatogram (XIC) of selected peptide masses. Automatic
peak assignment and retention times were veriﬁed manually.
After Savitzky−Golay smoothing, the peaks corresponding to
the precursor ion retention times were integrated and the
resulting peak areas were normalized to the endogenous actin
and then multiplied by a normalization factor of 100. The
normalized peak area was averaged across all acquisitions, and a
ratio was generated. p value was calculated by applying
Student’s t-test.
Metabolomics Analysis
100 μL of a mixture of ethanol/water 80:20 was added to ∼5 ×
106 cell pellets. Pellets were obtained by pooling cells of three
independent infection experiments. Cells were sonicated for 20
min; then, samples were centrifuged (25 000g, 4 °C, 20 min).
Supernatants were analyzed by an LC−MS/MS system
consisting of a Waters Alliance HT 2795 HPLC separation
module coupled to a Waters Quattro Ultima Pt ESI tandem
quadrupole mass spectrometer (Waters). The instrument was
operated in negative electrospray ionization mode using
MassLynx v. 4.0 software (Waters), and data processing was
performed using QuanLynx software (Waters). For HPLC
analysis, the Atlantis HILIC silica 3 μm 2.1 × 150 mm column
(Waters) was used. Thirty μL of the extracted samples was
injected onto the HPLC−MS/MS system. The technical
replicate was performed. The mobile phase comprised a binary
solvent system: acetonitrile (solvent A) and water containing
50 mmol/L ammonium acetate (solvent B). The initial solvent
composition was 100% A. 100% A was maintained for 3 min,
decreasing from the initial conditions to 50% A within 8.0 min,
holding for 4 min before returning to the initial state at 12.0
min, and allowing 4 min for column re-equilibration. The total
run time was 16 min, injection-to-injection. The ﬂow rate was
0.3 mL/min. The mass spectrometer ionization source settings
were optimized for maximum precursor ion yields for each
metabolite. This was achieved by infusing a 1 μg/mL
methanolic solution of each individual compound.47 The
following transitions were monitored for the metabolites of
interest: glucose 6-phosphate (G6P) 259.00 > 96.90, cone 40 V
and collision energy 13 eV; glyceraldehyde 3-phosphate (G3P)
168.90 > 96.90, cone 40 V and collision energy 6 eV;
phosphoenolpyruvate (PEP) 166.90 > 78.90, cone 40 V and
collision energy 7 eV; lactate (L) 89.00 > 43.00, cone 40 V and
collision energy 6 eV; malate (M) 133.00 > 115.00, cone 40 V
and collision energy 8 eV. The capillary voltage was 3.00 kV,
source temperature was 100 °C, desolvation temperature was
400 °C, and collision cell gas pressure was 3.5 × 10−3 mbar
argon. The interchannel and interscan delay times were 0.02
and 0.10 s, respectively. The dwell time was 0.200 s for each
analyte. The P value was calculated by applying Student’s t-test.
NADP+/NADPH was determined in 105 cell pellets, obtained
as previously described, for each sample at 565 nm by an
ultrasensitive colorimetric kit (EnzyChromTM NADP
+/NADPH Assay Kit, BioAssay Systems). p value was
calculated by applying Student’s t-test.
Western Blotting
Transduced CSCs were collected by centrifugation at 1200
rpm. Cell pellets were washed twice with ice-cold PBS,
resuspended in a 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1
mM EDTA, 1 mM NaF, 10% glycerol, 1 mM MgCl, 1% Triton
X-100 ice-cold buﬀer containing proteinase inhibitor cocktail
(Sigma-Aldrich), and incubated for 30′ on ice. Lysates were
centrifuged at 10 000g for 10′ and supernatants were collected.
2.5 μg of cell extracts were resolved on a 12% SDS-
polyacrylamide gel using a mini-gel apparatus (Bio-Rad
Laboratories). Western blots were performed as previously
described48 by using the following antibodies: anti-lactate
dehydrogenase (PA5-27406, Thermo Scientiﬁc), anti-PKM2
(PA-23034, Thermo Scientiﬁc), anti-G6PD (PA5-27359,
Thermo Scientiﬁc), anti-p63 (clone Y4A3, P3362, Sigma-
Aldrich), anti-β-Actin (clone AC-15, A5441 Sigma-Aldrich).
■ RESULTS
Quantitative Proteomics by Stable Isotope Dimethyl
Labeling and Functional Analysis of Modulated Proteins
To evaluate the eﬀect of p63 isoforms expression on cellular
processes, we employed a quantitative proteomic study. Colon
CSCs derived from a primary tumor as previously described28
were transduced with lentiviral vectors carrying either TA or
ΔNp63. Prior to proteomic analysis, TAp63α and ΔNp63α
expression were evaluated in cell extracts obtained 48 h
postinfection (Figure 1). Then, protein extracts of colon CSCs
transduced with empty vector, CTRL, and with vectors
overexpressing TAp63α or ΔNp63α were digested by trypsin
prior reaction with dimethyl labels. We employed an oﬀ line 2-
D peptide separation strategy using IEF in the ﬁrst step. The
labeled samples were mixed and loaded on 18 cm immobiline
dry strip, pH 3−10 NL, for peptides separation. The focused
Figure 1. Evaluation of αp63 expression 48 h postinfection.
Representative experiment of Western blotting showing the level of
TAp63α and ΔNp63α expression after 48 h of infection. Actin was
used as loading control.
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strips were cut in several pieces, and extracted peptides were
analyzed by nLC−MS/MS for protein identiﬁcation and
quantiﬁcation. The list of proteins modulated after TAp63
overexpression is reported in Table 1 (See Table 2S in the
Supporting Information for peptide identiﬁcation details). A
total of 51 proteins were found diﬀerentially regulated with
ratio above 1.3 or below 0.7, with peptides satisfying the quality
parameters reported in the Experimental Section (Figure 2).
Table 1. List of Modulated Proteins Identiﬁed by Chemical Quantitative Analysis in TAp63 Cells with Respect to Control Cells
accessiona descriptionb scorec massd TAp63/CTRLe SD(geo)f #g
AK1BA_HUMAN aldo-keto reductase family 1 member B10 105 37283 0.35 1.05 2
AK1C1_HUMAN aldo-keto reductase family 1 member C1 70 38055 0.35 1.01 2
HSP71_HUMAN heat shock 70 kDa protein 1A/1B 518 71696 0.36 1.36 6
METK2_HUMAN S-adenosylmethionine synthase isoform type-2 78 44841 0.4 1
LEG4_HUMAN galectin-4 268 36397 0.43 1
CH10_HUMAN 10 kDa heat shock protein 476 11233 0.49 1.54 5
CAPG_HUMAN macrophage-capping protein 86 39529 0.52 1
NPM_HUMAN nucleophosmin 417 33651 0.52 1.44 3
EF1G_HUMAN elongation factor 1-gamma 282 51455 0.53 1
IPYR_HUMAN inorganic pyrophosphatase 140 33880 0.53 1
KCRB_HUMAN creatine kinase B-type 302 43491 0.54 1.13 2
CH60_HUMAN 60 kDa heat shock protein 1432 62886 0.6 1.10 9
ECH1_HUMAN delta(3,5)-delta(2,4)-dienoyl-CoA isomerase 300 36612 0.6 1
ETFA_HUMAN electron transfer ﬂavoprotein subunit alpha 162 36129 0.6 1
UGDH_HUMAN UDP-glucose 6-dehydrogenase 648 56683 0.6 1.12 5
PRDX1_HUMAN peroxiredoxin-1 298 22857 0.61 1
HSPB1_HUMAN heat shock protein beta-1 586 23022 0.62 1.08 5
MDHM_HUMAN malate dehydrogenase 702 36666 0.62 1.19 8
ECHM_HUMAN enoyl-CoA hydratase 169 32496 0.63 1
H33_HUMAN histone H3.3 122 15740 0.63 1.32 4
IF4A1_HUMAN eukaryotic initiation factor 4A-I 132 46913 0.63 1.25 2
K1C19_HUMAN keratin, type I cytoskeletal 19 678 44472 0.63 1.13 5
TKT_HUMAN transketolase 581 69696 0.63 1.07 7
HNRPQ_HUMAN heterogeneous nuclear ribonucleoprotein Q 61 71077 0.67 1
ADT2_HUMAN ADP/ATP translocase 2 341 33704 0.68 1.42 4
HNRPK_HUMAN heterogeneous nuclear ribonucleoprotein K 554 51846 0.68 1.12 4
GRP75_HUMAN stress-70 protein 659 75378 0.69 1.27 3
AGR2_HUMAN anterior gradient protein 2 homologue 106 20528 0.69 1.48 3
DHSA_HUMAN succinate dehydrogenase 317 74485 0.69 1.32 2
HSP7C_HUMAN heat shock cognate 71 kDa protein 1004 72596 0.69 1.33 7
LMNA_HUMAN prelamin-A/C 487 75501 0.69 1.38 6
H2A2A_HUMAN histone H2A type 2-A 769 14479 1.32 1.23 10
SERA_HUMAN D-3-phosphoglycerate dehydrogenase 46 58189 1.33 1
PPIB_HUMAN peptidyl-prolyl cis−trans isomerase B 164 24513 1.35 1.30 4
1433T_HUMAN 14-3-3 protein theta 347 28564 1.36 1
TCPD_HUMAN T-complex protein 1 subunit delta 173 59494 1.36 1.12 2
FLNA_HUMAN ﬁlamin-A 553 287786 1.43 1
GANAB_HUMAN neutral alpha-glucosidase AB 219 108128 1.45 1.10 2
TBB5_HUMAN tubulin beta chain 993 50576 1.48 1
PUR6_HUMAN multifunctional protein ADE2 138 48772 1.48 1
WDR1_HUMAN WD repeat-containing protein 1 110 67957 1.51 1
IQGA1_HUMAN Ras GTPase-activating-like protein 142 194057 1.52 1
RLA1_HUMAN 60S acidic ribosomal protein P1 144 11845 1.54 1
SPTN1_HUMAN spectrin alpha chain 275 290713 1.63 1
H2B1C_HUMAN histone H2B type 1-C/E/F/G/I 358 14458 1.65 1
UBA1_HUMAN ubiquitin-like modiﬁer-activating enzyme 1 440 120343 1.69 1
HNRPL_HUMAN heterogeneous nuclear ribonucleoprotein L 124 65533 1.71 1
DHX9_HUMAN ATP-dependent RNA helicase A 174 144264 1.85 1
RS10_HUMAN 40S ribosomal protein S10 68 19250 2.44 1
NDUAD_HUMAN NADH dehydrogenase [ubiquinone] 1 58 16880 3.52 1
CSPG4_HUMAN chondroitin sulfate proteoglycan 104 251996 4.54 1
aID protein according to SwissProt database. bProtein description. cMascot score. Only proteins identiﬁed with score >40 were reported. dProtein
mass. eProtein ratio TAp63/CTRL, expressed as median. Only proteins with a ratio >1.3 and <0.7 are reported. fSD (geo) = geometric standard
deviation calculated by Distiller; when absent the number of peptides was insuﬃcient to calculate it. gNumber of peptides used for quantitation.
Underlined proteins indicated proteins validated in targeted label free experiment.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr4012574 | J. Proteome Res. 2014, 13, 2120−21362125
Reported proteins were identiﬁed with Mascot score above 40
and FDR < 1%. In the case of ΔNp63 transfected cells, after
data processing and database search a total of 38 proteins were
found modulated with ratio above 1.3 or below 0.7, whose
peptides satisﬁed the quality parameters reported in the
Experimental Section (Figure 2). All reported proteins were
identiﬁed with Mascot score above 40 and FDR < 1% (Table 2
and Table 3S in the Supporting Information).
Proteins listed in Tables 1 and 2 were used as input ﬁles for
PANTHER Classiﬁcation System to classify the biological
processes regulated by the proteins modulated in TAp63 and
ΔNp63 data set, respectively (Figure 3). As shown in pie
charts, apoptosis is the discriminating biological process
between the two data sets. NAD-dehydrogenase (NDUAD,
GRIM-19), annotated as apoptotic inducers in Panther
database, was found to be up-regulated in TAp63 over-
expressing cells, whereas galectin-4 (LEG4) and heterogeneous
nuclear ribonucleoprotein K (HNRPK), also associated with
induction of apoptosis process, were found down-regulated.
Interestingly, in both data sets a great part of the modulated
proteins was involved in metabolic process, representing 35.1
and 30.3% of the pie chart in TAp63 and ΔNp63 experiments,
respectively. Moreover, in both cases, proteins associated with
the generation of precursor metabolites and energy were
highlighted, underlining the possible involvement of both p63
isoforms in regulating cancer cells metabolism. Proteins
included in this biological process were found to be down-
regulated after transfection with TAp63 expressing vector. They
were: UDP-glucose 6-dehydrogenase (UGDH) involved in
biosynthesis of glycosaminoglycans, mitochondrial succinate
dehydrogenase (DHSA) and mitochondrial malate dehydro-
genase (MDHM) belonging to tricarboxylic acid (TCA) cycle,
and mitochondrial electron transfer ﬂavoprotein subunit alpha
(ETFA), which transfers electrons to the main mitochondrial
respiratory chain. In the ΔNp63 data set, proteins associated
with this biological process, ATP-citrate synthase (ACLY) and
Figure 2. Peptides data quality evaluation for TAp63 (A−F) and ΔNp63 (G−H) data sets. Bar charts showing peptide identiﬁcation results: Mascot
score (A,G), experimental mass error (B,H), and intensity distribution (C,I). Moreover quality parameters for peak detection are displayed: Standard
error (D, L), fraction (E,M), and correlation (F,N). (See the Experimental Section for more details.) Gray points represent discarded peptides.
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cytoplasmic malate dehydrogenase (MDHC), were found to be
up-regulated in transfected cells. In mitochondria, ACLY uses
acetyl-CoA and oxaloacetate to produce citrate, which is
transported to the cytosol. Here citrate is used by citrate lyase
to generate acetyl-CoA, while the resulting oxaloacetate is
converted to malate by cytoplasmic MDH, thus producing
NADPH. The observed modulation of both ACLY and
cytoplasmic MDH suggested an increased production of
Table 2. List of Modulated Proteins Identiﬁed by Chemical Quantitative Analysis in ΔNp63 Cells with Respect to Control Cells
accessiona descriptionb scorec massd ΔNp63/CTRLe SD(geo)f #g
CLIC1_HUMAN chloride intracellular channel protein 1 137 27825 0.21 1
HSP71_HUMAN heat shock 70 kDa protein 1A/1B 577 71696 0.36 1
AK1BA_HUMAN aldo-keto reductase family 1 76 37150 0.46 1
MIF_HUMAN macrophage migration inhibitory factor 42 12735 0.48 1
S100P_HUMAN protein S100-P 52 10731 0.53 1
PTBP1_HUMAN polypyrimidine tract-binding protein 1 233 58282 0.60 1.35 3
EZRI_HUMAN ezrin 58 71247 0.62 1
METK2_HUMAN S-adenosylmethionine synthase 46 44732 0.64 1
RL30_HUMAN 60S ribosomal protein L30 136 13396 0.66 1
CH10_HUMAN 10 kDa heat shock protein 280 11277 0.67 1.43 5
G6PI_HUMAN glucose-6-phosphate isomerase 424 64316 0.68 1.10 4
RL5_HUMAN 60S ribosomal protein L5 88 35550 0.69 1
KCRB_HUMAN creatine kinase B-type 179 43491 0.70 1
FAS_HUMAN fatty acid synthase 696 278602 1.30 1.03 5
GSTP1_HUMAN glutathione S-transferase P 128 23905 1.31 1.35 3
ARP3B_HUMAN actin-related protein 3B 51 48764 1.32 1
ACTN4_HUMAN alpha-actinin-4 515 106870 1.32 1
MDHC_HUMAN malate dehydrogenase 139 37500 1.39 1
LPPRC_HUMAN leucine-rich PPR motif-containing protein 60 162272 1.40 1
SAHH_HUMAN adenosylhomocysteinase 62 49185 1.40 1
HNRPF_HUMAN heterogeneous nuclear ribonucleoprotein F 149 46433 1.40 1
HYOU1_HUMAN hypoxia up-regulated protein 1 232 113963 1.42 1
PPIB_HUMAN peptidyl-prolyl cis−trans isomerase B 93 24618 1.42 1
ACLY_HUMAN ATP-citrate synthase 47 123982 1.42 1
ANXA5_HUMAN annexin A5 159 36677 1.43 1
RS14_HUMAN 40S ribosomal protein S14 48 16867 1.52 1
K1C18_HUMAN keratin, type I cytoskeletal 18 487 48617 1.53 1.39 6
IPYR_HUMAN inorganic pyrophosphatase 76 33993 1.62 1
CALX_HUMAN calnexin 128 69524 1.62 1
HSP74_HUMAN heat shock 70 kDa protein 4 84 97723 1.63 1
K1C19_HUMAN Keratin, type I cytoskeletal 19 302 44472 1.69 1
WDR1_HUMAN WD repeat-containing protein 1 61 68118 1.86 1
EF1D_HUMAN elongation factor 1-delta 70 31777 1.90 1
PELP1_HUMAN proline-, glutamic acid-, and leucine-rich protein 1 48 121440 1.95 1
MATR3_HUMAN matrin-3 53 96928 2.12 1
HSP7C_HUMAN heat shock cognate 71 kDa 536 72596 2.16 1
CSPG4_HUMAN chondroitin sulfate proteoglycan 4 192 251880 2.22 1.24 2
aID protein according to SwissProt database. bProtein description. cMascot score. Only protein identiﬁed with score >40 were reported. dProtein
mass. eProtein ratio ΔNp63/CTRL, expressed as median. Only protein with a ratio >1.3 and <0.7 are reported. fSD (geo) = geometric standard
deviation calculated by Distiller; when absent the number of peptides was insuﬃcient to calculate it. gNumber of peptides used for quantitation.
Underlined proteins indicated proteins validated in targeted label free experiment.
Figure 3. Functional analysis by PANTHER classiﬁcation system. Pie charts showing biological processes of modulated proteins found in TAp63
(A) and ΔNp63 (B).
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acetyl-CoA, which can be used in lipid synthesis. Moreover
fatty acid synthetase (FAS) was found to be up-regulated in
ΔNp63 expressing cells.
Molecular and cellular functions were investigated also by
Ingenuity Pathway Analysis software (IPA) (Table 3). Results
emphasized the perturbation of metabolic process and process
associated with cellular assembly and organization in TAp63
experiment and cell death and survival, cellular function and
maintenance, cell cycle, cell morphology, and cellular assembly
and organization in ΔNp63 experiment.
Performing functional annotation cluster by DAVID in
TAp63 data set, functions associated with stress response and
protein folding were enriched in cluster 1 with a score of 3.55
(Table 4S in the Supporting Information). Interestingly the
second ranked cluster was prevalently associated with
mitochondrion and organelle lumen (enrichment score =
3.19), thus indicating alterations of mitochondrial processes
after TAp63 expression. In particular, NADH dehydrogenase
(NDUAD), creatine kinase (KKRB), ETFA, enoyl coenzyme A
hydratase (ECHM), four heat shock proteins (CH10, CH60,
HSP71, and GRP75), MDHM, peroxiredoxin 1 (PRDX1),
solute carrier family 25 (ADT2, ADP/ATP translocase 2), and
DHSA were associated with mitochondrion in cluster 2.
Submitting ΔNp63 data set to DAVID, the enriched Cluster
1, with score of 2.83, was mostly composed of proteins
associated with stress response, heat shock proteins, ATP, or
nucleoside binding, indicating the modulation of energy
metabolism and nucleic acid metabolism after ΔNp63
expression (Table 5S in the Supporting Information).
To investigate TAp63- and ΔNp63-mediated cellular signal-
ing, we performed an unsupervised bioinformatics analysis
using IPA. Known mutual interactions among diﬀerentially
expressed proteins were used to construct protein networks
ranked by score (Table 4). In the TAp63 experiment, the
network generated with higher score and associated with
energy production, nucleic acid metabolism, and small molecule
biochemistry functions (Figure 4A) was constructed by some of
the already cited proteins, such as heat shock proteins, CKRB,
ECHM, MDHM, PRDX1, ADT2 (SLC25A5), and UGDH.
The main nodes deduced by IPA were represented by Akt and
MAPK1/2, which are known to be essential for glucose
homeostasis.49 Network with higher score in ΔNp63 experi-
ment was associated with cancer, tumor morphology, cell death,
and survival (Figure 2B). Relevant modulated proteins of this
network were: heat shock proteins, structural proteins such as
keratins (K1C18), actinin 4 (ACTN4), and actin-binding
protein, which is associated with cell motility and cancer
metastasis,50 ezrin (EZR), involved in maintaining the cell
cortex,51 and enzymes, such as CKRB and glucose-6-phosphate
isomerase (G6PI, GPI in the network). Interestingly, the main
node of the network deduced by the software was Akt, thus
underlining similarity with TAp63. Similarly to TAp63,
metabolism was also reported as a relevant network function,
although with lower score (score = 27), associated with
carbohydrate metabolism, RNA post-transcriptional modiﬁca-
tion, and post-translational modiﬁcation in network 2 (Table
3). In silico analysis allowed us to highlight also possible
upstream regulators of the reported networks. In both TAp63
and ΔNp63 experiment, Myc was predicted to be modulated
with signiﬁcant score (Figure 5A). Moreover, in the case of
ΔNp63 in addition to Myc, also p53 was predicted to be
modulated (Figure 5B).
Targeted Label-Free Quantitative Analysis
To validate experimental evidence found by quantitative labeled
proteomic investigation followed by in silico functional analysis,
we carried out a targeted label-free strategy to quantify the
proteotypic peptides of regulated proteins of interest. Whole
protein extracts of CTRL, TAp63, and ΔNp63-transfected cells
were digested by trypsin and loaded on a nanoACQUITY
UPLC system coupled to a Q-TOF mass spectrometer
operating in high−low mode. Triplicates were run for each
condition. Raw data were ﬁrst analyzed to evaluate chromato-
graphic reproducibility and processed by PLGS software, using
SwissProt database restricted to Homo sapiens taxonomy, to
evaluate the number of total identiﬁed proteins. (Representa-
tive protein lists identiﬁed in a single run of each condition,
with FPR < 1%, are reported in Table 6S in the Supporting
Information.) The EMRT (exact mass retention time) peptide
clusters, that is, the list of paired exact masses and retention
times42−44 found by the software, showed RSD (relative
standard deviation) mass below 15 ppm and %CV RT
(coeﬃcient variation on retention time) mostly below 6%,
Table 3. Ingenuity Pathway Analysis Results: List of
Signiﬁcant Molecular and Cellular Function
molecular and cellular function p value
no. of
molecules
TAp63 Experiment
cellular assembly and
organization
3.06 × 10−6 to
4.73 × 10−2
15
energy production 8.94 × 10−6 to
2.10 × 10−2
7
nucleic acid metabolism 8.94 × 10−6 to
3.28 × 10−2
11
small-molecule metabolism 8.94 × 10−6 to
4.62 × 10−2
20
post-translational modiﬁcation 8.87 × 10−5 to
2.69 × 10−2
8
ΔNp63 Experiment
cell death and survival 6.45 × 10−6 to
4.05 × 10−2
21
cellular function and
maintenance
8.73 × 10−5 to
4.16 × 10−2
13
cell cycle 1.79 × 10−4 to
4.78 × 10−2
13
cell morphology 1.79 × 10−4 to
4.29 × 10−2
10
cellular assembly and
organization
1.79 × 10−4 to
4.04 × 10−2
16
Table 4. Ingenuity Pathway Analysis Results: List of
Signiﬁcant Networks
network associated network functions score
TAp63
Experiment
1 energy production, nucleic acid metabolism, small-
molecule biochemistry
58
2 developmental disorder, hereditary disorder, metabolic
disease
29
3 tissue morphology, cell morphology, hematological
system development and function
21
ΔNp63
Experiment
1 cancer, tumor morphology, cell death and survival 51
2 RNA post-transcriptional modiﬁcation, post-
translational modiﬁcation, carbohydrate metabolism
27
3 hematological disease, hereditary disorder, tissue
morphology
13
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and %CV intensity (coeﬃcient variation of EMRTs intensities)
showed Gaussian distributions centered on mean value of ∼2%
CV under the three conditions (Figure 1S in the Supporting
Information). Raw data were then used to generate extracted
Figure 4. Pathway analysis. (A) Network generated for TAp63 experiment, showing score = 58, was involved in energy production, nucleic acid
metabolism, and small-molecule biochemistry. (B) Network with higher score in ΔNp63 experiment was associated with cancer, tumor morphology,
cell death, and survival. Nodes represent proteins: shaded features describe proteins identiﬁed in the present study (red, up-regulated; green, down-
regulated), whereas unshaded features describe additional members deduced by the software.
Figure 5. Upstream regulators predicted by in silico analysis. In TAp63, Myc was predicted to be modulated with signiﬁcant p value = 3.07 × 10−7
(A), while in ΔNp63 experiment, Myc and p53 were predicted to be modulated, p value = 4.23 × 10−7 and 3.65 × 10−6 (B).
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ion chromatograms (XICs) by Skyline software. XIC traces of
MS1 traces were used for integrating peak area and determining
the abundance of proteotypic peptides of interesting proteins
with respect to actin proteotypic peptides, used for normal-
ization. The following proteins were included in this
investigation: mitochondrial heat shock proteins (HSP10,
HSP60, and HSP71), alpha actinin 4 (ACTN4), cytokeratin-
18 (K1C18), and some metabolic enzymes, such as glucose-6-
phosphate isomerase (G6PI), mitochondrial malate dehydro-
genase (MDHM), UDP-glucose 6-dehydrogenase (UGDH),
triosephosphate isomerase (TPIS), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), and transketolase (TKT) (Figure
6A. Proteins were quantiﬁed using two proteotypic peptides
(with the exception of CH10, HSP71, and UGDH), with a
percentage of coeﬃcient of variation (%CV) for peptide
retention times (RTs) below 5% and a %CV calculated for
normalized peak area below 30% or close to this value (Table
5). Enolase from S. cerevisiae (ENO1) and human enolase alpha
(ENOA) were used as control proteins, whose abundance is
not expected to be modulated. ENO1 was added as standard in
samples prior to acquisition (see the Experimental Section),
while ENOA was not found among the signiﬁcant modulated
proteins in both ΔNp63 and TAp63 data sets. Mitochondrial
heat shock proteins (HSP10, HSP60, and HSP71), included in
mitochondrion and organelle lumen cluster by DAVID analysis
and represented among the modulated nodes in network 1 of
IPA analysis in TAp63 experiment, were conﬁrmed to be down-
regulated with respect to CTRL condition by targeted label-free
experiment. Down-regulation of HSP10 was also conﬁrmed for
ΔNp63 experiment. UGDH and MDHM, reported in network
1 of TAp63 IPA analysis and members of the PANTHER
biological process called generation of precursor metabolites
and energy, were found to be down-regulated in TAP63 by
labeled approach. These enzymes showed a decrement with
respect to control cells also in the targeted analysis, although
the trend was more evident in the case of UGDH rather than in
Figure 6. (A) Targeted proteomic analysis. LC−MS/MS runs of unlabeled samples were processed by Skyline software to quantify proteotypic
peptides of interesting proteins. ACTN4, alpha actinin 4; CH10, 10 kDa heat shock protein, mitochondrial; CH60, 60 kDa heat shock protein,
mitochondrial; HSP71, heat shock 70 kDa protein 1A/1B; G6PI, glucose-6-phosphate isomerase; TPIS, triosephosphate isomerase; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; cytoskeletal keratin-18 (K1C18); mitochondrial malate dehydrogenase (MDHM), UDP-glucose 6-
dehydrogenase (UGDH). Protein abundance is reported as peaks area generated by XIC after normalization. Endogenous actin was used as standard
for normalization. Error bars represent standard deviation calculated on three diﬀerent analytical runs. Asterisks indicate statistical signiﬁcance (t test
p value < 0.05 for TAp63 or ΔNp63 cells vs control cells). More details are reported in Table 5. (B) Targeted metabolomics analysis. Metabolites
were extracted from CTRL, TAp63, and ΔNp63 cells. Glucose 6-phosphate (G6P), glyceraldehyde 3-phosphate (G3P), phosphoenolpyruvate
(PEP), lactate (L), and malate (M) were determined by mass spectrometry and reported as relative response (arbitrary units, calculated as the peak
area of each analyte normalized to the total chromatographic peak areas). Error bars represent standard deviation calculated on three diﬀerent
analytical runs. Asterisks indicate statistical signiﬁcance (p value< 0.05 t test of TAp63 or ΔNp63 cells vs control cells.) (C) Immunoblotting analysis.
Western-blotting analysis was carried out using whole cell lysate from CTRL, TAp63, and ΔNp63 cells and antibodies against LDHA (lactate
dehydrogenase A chain), G6PD (glucose-6-phosphate 1-dehydrogenase), and PKM2 (pyruvate kinase). Actin was used as loading control. (D)
Measurement of NADP and NADPH. Asterisks indicate statistical signiﬁcance (p value< 0.05 t test of TAp63 or ΔNp63 cells vs control cells). (E)
Determination of NADP/NADPH ratio. Asterisks indicate statistical signiﬁcance (p value< 0.05 t test of TAp63 or ΔNp63 cells vs control cells).
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MDHM. TKT, belonging to pentose phosphate pathway
(PPP), was found to be decreased in label-free analysis in
TAp63 overexpressing cells, as already observed by labeled
approach. Trends of ACTN4, K1C18, and G6PI, included in
network 1 of ΔNp63, were also conﬁrmed in this validating
phase: ACTN4 and K1C18 showed a marked increment in
ΔNp63, whereas G6PI was decreased with respect to control
condition.
Targeted Metabolomics Analysis
To better characterize the metabolic state of TAp63 and
ΔNp63 expressing cells, we performed a targeted metabolomics
analysis, evaluating the cellular relative abundance of ﬁve
relevant metabolites for the reported biochemical pathways by
monitoring their mass spectrometry transitions: glucose 6-
phosphate (G6P), glyceraldehyde 3-phosphate (G3P), phos-
phoenolpyruvate (PEP), lactate (L), and malate (M) (Figure
6B). Results showed signiﬁcant accumulation of G6P and G3P
in ΔNp63 cells, while these metabolites were less abundant in
TAp63 cells, with respect to control condition. Accumulation of
substrates of the ﬁrst steps of glycolysis, such as G6P and G3P,
was associated with decreased levels of G6PI, TPIS, and
GAPDH in ΔNp63 cells. G6PI was found to be down-regulated
by both labeled and unlabeled proteomic analysis, while TPIS
and GAPDH were reported only for the label-free proteomic
strategy, although in the labeled approach TPIS showed a fold
change of 0.8 with respect to control conditions, which was
omitted in the corresponding table because under the selected
threshold for ratio. These results may be indicative of a slower
rate of the ﬁrst steps of glycolysis under this condition with
respect to control cells. In anaerobic glycolysis, lactate
dehydrogenase (LDHA) reduces pyruvate to produce lactate
(L), using NAD as coenzyme. In ΔNp63 cells, a signiﬁcant
increment of L was not observed by targeted metabolomics
analysis, and insigniﬁcant modulation of LDHA protein was
detected (Figure 6C). Moreover, in these cells, we did not
detect a modulation in protein level of pyruvate kinase (PKM2)
(Figure 6C), a key regulatory enzyme of glycolytic pathway that
catalyzes the transfer of a phosphate group from PEP to ADP,
yielding one molecule of pyruvate and one molecule of ATP.
Furthermore, PPP may be less favored in ΔNp63-expressing
cells, as indicated by the down-regulation of glucose-6-
phospate-dehydrogenase (G6PD), the enzyme controlling the
rate-limiting step of PPP, as observed by Western blotting
experiment (Figure 6C), and by the decrement of NADP/
NADPH ratio, which was caused by reduced NADP availability
rather than enhanced NADPH production (Figure 6D,E). In
TAp63 overexpressing cells, the decrease in G6P and G3P was
accompanied by moderate up-regulation of G6PI and GAPDH,
observed in both proteomic approaches (although the fold
change of 1.22 for GAPDH was not reported in Table 1
because it was under the threshold ﬁxed for ratio) and TPIS
only in label-free approach, underlining a possible opposite
eﬀect of the two p63 isoforms on glycolysis. Glycolysis may be
accelerated in TAp63, as also indicated by up-regulation of
PKM2, detected by Western blotting (Figure 6C), which
rapidly converts PEP to pyruvate. Unlike ΔNp63 cells, under
TAp63 condition PEP, L and M were signiﬁcantly less
abundant with respect to control. LDHA was lightly up-
regulated, while modulation of G6PD was not detected in
TAp63 cells by Western blotting (Figure 6C). The NADP/
NADPH ratio was approximately the same as that determined
in control cells (Figure 6D,E). Interestingly, the reduced
amount of malate, a TCA intermediate, was associated with the
reduced levels of two TCA cycle enzymes, such as succinate
dehydrogenase (DHSA), reported only in labeled proteomic
analysis, and MDHM, in both labeled and label-free proteomic
analysis.
■ DISCUSSION
On the basis of the knowledge of p63’s role in the regulation of
epithelial cell stemness and diﬀerentiation, it is reasonable to
suspect that it may also play a role in regulating the phenotypic
characteristics of CSCs through the control of several molecular
pathways, including self-renewal and diﬀerentiation processes.23
Recent studies reported that ΔNp63 isoforms can regulate the
mRNA expression and splicing of CD44, a surface glycoprotein
marking CSCs in various epithelial tumors including HNSCC
and breast cancer.52 ΔNp63α induces a stem-cell phenotype in
the MCF7 breast cancer cell line, and it has been suggested that
it could be a marker of breast CSC.53 Recently, it was reported
that ΔNp63-positive cells embody the stem/progenitor proper-
ties in prostate, bladder, and colorectal epithelium, providing a
potential source of cells that can diﬀerentiate into neoplastic
cells.19
In this study, we used CSCs isolated from colon, over-
expressing TAp63α or ΔNp63α, to evaluate cellular signaling
mediated by the two isoforms, following a quantitative labeled
proteomic strategy, coupled to functional in silico analysis.
A substantial number of proteins modulated by both p63
isoforms belong to cellular assembly and organization and to
cellular morphology, among which there are also proteins
involved in tumor progression and metastasis. Chondroitin
sulfate proteoglycan 4, CSPG4, a surface protein that is known
to modulate oligodendrocyte precursor cells migration54 and to
be associated with invasiveness in glioma and melanoma
tumors,55 was found increased in both TAp63- and ΔNp63-
expressing cells. Other structural proteins involved in cellular
migration were found up-regulated, such as ﬁlamin-A (FLNA)
in TAp63 and actinin-4 (ACTN4) in ΔNp63, respectively.
FLNA is an actin-binding protein playing an essential role in
cytoskeletal plasticity and ﬂexibility to respond to environ-
mental stimuli by interacting with extracellular matrix (ECM)
components.56 FLNA also interacts with many metastasis-
related proteins, and its inhibition may reduce this process,
although the mechanism of action remains not completely
clariﬁed.57 ACTN4 is a component of focal adhesion, protein
complexes that mediate cell migration by physically connecting
the ECM to the cytoskeleton.58 These ﬁndings suggested the
involvement of p63 in metastatic process of CSCs, as already
observed in other cellular model of cancer.11,14
Interestingly a signiﬁcant portion of modulated proteins,
reported in this work, were involved in metabolic processes. A
common distinct feature of cancer cells is the so-called “aerobic
glycolysis”, which consists of enhanced lactate production,
originally known as Warburg eﬀect.59 However, metabolic
rearrangement is not limited to glycolysis but also involves the
TCA cycle, β-oxidation, and anabolic metabolism in general by
furnishing not only energy but also components for the
synthesis of nucleotides and amino and fatty acids to sustain
cellular growth and survival.60 In the recent years, it is
becoming clear that diﬀerent key cellular signals guide the
metabolic adaptation of tumor cells, such as hypoxia inducible
factor-1 (HIF-1) and PI3K/Akt/mTOR pathways, oncogenes
such as c-Myc, and tumor suppressor such as p53.61 Under
hypoxia condition, HIF-1 activates the transcription of genes
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encoding glucose transporters and most glycolytic enzymes,
increasing the glycolytic activity of cells. Moreover, by
activating pyruvate dehydrogenase kinases (PDKs), which
inhibits mitochondrial pyruvate dehydrogenase complex, HIF-
1 reduces pyruvate ﬂux into the TCA cycle, thus decreasing
oxidative phosphorylation and oxygen consumption.61 The
oncogene c-Myc activates glucose transporters, glycolytic
enzymes, LDHA and PDK1, and genes involved in
mitochondrial biogenesis and function, such as those associated
with glutamine metabolism.61 Activation of PI3K/Akt/mTOR
pathway leads to enhanced glycolytic activity by both elevated
synthesis of glucose transporters and activation of HIF-1, which
cooperates with c-Myc to induce metabolic adaptation in
cancer cells.61 Finally, p53 takes part in the regulation of
glucose metabolism, acting on enzymes involved in glycolysis,
TCA cycle, glutaminolysis, and PPP.61 In particular, p53
directly inactivates G6PD, thus inhibiting PPP, while mutated
p53 is unable to perform this function, thus causing the
increased consumption of glucose, typical of tumor cells.62 On
the contrary, TAp73, but not ΔNp73, promotes biosynthesis
and antioxidant protection through the induction of G6PD
expression.58 Moreover, overexpression of TAp73α in human
osteosarcoma SAOS-2 promotes PPP process.64 Flores and
colleagues demonstrated that TAp63 regulates several meta-
bolic pathways, through which it may establish its tumor
suppressor functions.65 Mice knockout of TAp63 became
obese, accumulating lipid deposits in several tissues. This
phenotype can be explained by an increased fatty acid synthesis
associated with a concomitant decrease in fatty acid
consumption. Moreover, these mice also developed defects in
glucose metabolism. Furthermore, TAp63−/− mouse embry-
onic ﬁbroblasts (MEFs) showed a slower rate of mitochondrial
oxidative phosphorylation, which is a peculiar metabolic
alteration of cancer cells, and reduced glucose uptake, which,
on the contrary, is in contrast with that observed in tumor
cells.65
In this study, the in silico functional analysis highlighted the
modulation of cellular signaling responsible for metabolic
adaptation in the cancer cell, such as c-Myc and PI3K/Akt/
mTOR, in both TAp63- and ΔNp63-overexpressing cells, and
p53, only in ΔNp63-expressing cells. Proteins and metabolites
of glycolysis were modulated in TAp63- and ΔNp63-expressing
cells but with opposite trends. In TAp63-overexpressing cells
the level of glycolytic intermediates determined by targeted
analysis was signiﬁcantly inferior to that observed in control
cells. In parallel, we observed the increased levels of glycolytic
enzymes, such as G6PI, TPIS, GAPDH, and PKM2. G6PI,
which catalyzes the second step of the glycolysis by the
reversible isomerization of glucose-6-phosphate into fructose-6-
phosphate, is an essential enzyme involved in catabolic
glycolysis, anabolic gluconeogenesis, and it is known to
inﬂuence tumor cell growth.60 Deﬁciency of TPIS, another
essential glycolytic enzyme, is associated with nonspherocytic
hemolytic anemia and a severe neurological disorder, while its
up-regulation has been reported in several cancers, including
lung, liver, colon, breast, bone, and prostate.60 Onco-
proteomics studies showed that also GAPDH is overexpressed
in various neoplasias.60 In addition to glycolysis, GAPDH is
involved in diﬀerent biological functions, such as DNA repair
and telomeric DNA binding, transcriptional regulation,
membrane fusion, RNA binding, tubulin assembly, and
apoptosis induction.60 Pyruvate kinase (PK) is a key regulatory
enzyme, catalyzing an irreversible reaction of the glycolysis. L,
R, M1, and M2 are the four PK isoenzymes in mammals.
Among them, the PKM2 isoenzyme is preferentially expressed
in tumor cells.60 G6PI, TPIS, and GAPDH are signiﬁcantly
down-regulated in ΔNp63-expressing cells. Also, G6PD was
detected in lower quantity in ΔNp63 as compared with control
and TAp63 conditions. Moreover, the down-regulation of TCA
cycle enzymes, such as DHSA and MDHM, and the lower level
of malate may be suggestive of a perturbed mitochondrial
oxidative phosphorylation in TAp63- expressing cells. Modu-
lation of other proteins associated with mitochondrion, such as
HSP10, HSP60, and HSP71, was indicative of an altered
function of this organelle, particularly in TAp63-expressing
cells.
Mitochondria play a key role not only in energy production
but also in the cross-talk of metabolic pathways and signals for
apoptosis and autophagy.66,67 Mitochondrial functions are
carried out by continuous signal exchanges both from nucleus
to mitochondrion, anterograde signaling, and from mitochond-
rion to nucleus, retrograde signaling.66 An example of
retrograde signaling is represented by the mitochondrial
unfolded protein response, originated from the eﬄux of
peptides from damaged mitochondrial matrix proteins to the
cytosol, which is mediated by mitochondrial HSPs. Mitochon-
drial chaperones promote protein folding and proteases that
degrade misfolded proteins, leading to more eﬃcient
mitochondrial function and biogenesis.66
The cross-talk of the mitochondrial proteins with the nuclear
encoded proteins is a fundamental task of Mitochondrial
Proteome Initiative (mt-HPP),68 which will strictly cooperate
with the Biology/Disease Human Proteome Project (B/D-
HPP),69 one of the most recent initiatives launched by the
Human Proteome Organization. The present study provides
initial evidence toward dissecting p63 functions in CSCs,
although additional studies are required to go deeper inside this
issue to achieve new insight into the signaling pathways beyond
the diﬀerences in metabolism response correlated to TAp63 or
ΔNp63 expression. Nevertheless, evidence described here
could be matter of debate inside the scientiﬁc community
involved in both mt-HPP and B/D-HPP.
In conclusion, in this work, we employed a proteomic study,
by both labeled and unlabeled approaches, coupled to
bioinformatics and targeted metabolomics analysis to dissect
the intracellular pathways triggered by TAp63 or ΔNp63
isoforms in human CSCs line isolated from colon cancer. Our
results indicate that p63 is implicated in a wide range of
biological processes, including metabolism. Interestingly,
TAp63-overexpressing cells are more glycolytic active than
ΔNp63 cells, indicating that the two isoforms may regulate the
key steps of glycolysis in an opposite manner. Further
investigations are necessary to elucidate the underlying
molecular mechanisms determining glycolysis regulation by
TAp63 and ΔNp63 isoforms.
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